Protective effects of ultrasound-based preoperative exogenous sacubitril/valsartan on the heart and kidney of patients undergoing percutaneous coronary intervention

This research aimed to demonstrate the protective effects of exogenous sacubitril/valsartan on the heart and kidney of patients undergoing percutaneous coronary intervention (PCI) preoperatively based on ultrasound. Three hundred patients undergoing PCI in our hospital were assigned to a control (Ctrl) group (150 patients receiving valsartan preoperatively) and a research (Res) group (150 patients receiving sacubitril/valsartan preoperatively). The myocardial injury, cardiac function (CF), renal function (RF) and complications of the two groups were compared preoperatively and postoperatively. The results showed that the troponin I (cTnI) and creatine kinase isoenzyme myocardial bands (CK-MB) in the two groups showed a decreasing trend postoperatively, and that of the Res group was more significant (p < 0.05). Postoperatively, the left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) of the two groups of patients decreased, being more significant in the Res group (p < 0.05). Postoperatively, blood urea nitrogen (BUN) and creatinine (Cr) in the two groups were decreased, the trend being more evident in the Res group (p < 0.05). The drug efficiency in the Ctrl group and Res group was 84.67% and 93.33%, respectively, and the effective rate of drugs in the Res group was y higher (p < 0.05). In summary, ultrasonography had a positive adoption value in evaluating the treatment effect of coronary intervention, and exogenous sacubitril/valsartan had an important protective effect on the heart and kidneys of patients undergoing PCI.